For: | Dip N, Reis ST, Viana NI, Morais DR, Moura CM, Katz B, Abe DK, Iscaife A, Silva IA, Srougi M, Leite KR. MiRNA in bladder carcinogenesis: A review. World J Clin Urol 2014; 3(3): 238-248 [DOI: 10.5410/wjcu.v3.i3.238] |
---|---|
URL: | https://www.wjgnet.com/2219-2816/full/v3/i3/238.htm |
Number | Citing Articles |
1 |
Lili Sun, Junjian Zhang, Yunwei Li. Chronic central miR-29b antagonism alleviates angiotensin II-induced hypertension and vascular endothelial dysfunction. Life Sciences 2019; 235: 116862 doi: 10.1016/j.lfs.2019.116862
|
2 |
Pooja Jain, Himanshu Kathuria, Munira Momin. Clinical therapies and nano drug delivery systems for urinary bladder cancer. Pharmacology & Therapeutics 2021; 226: 107871 doi: 10.1016/j.pharmthera.2021.107871
|
3 |
Whi-An Kwon, Ho Kyung Seo. Emerging agents for the treatment of metastatic urothelial cancer. Investigative and Clinical Urology 2021; 62(3): 243 doi: 10.4111/icu.20200597
|
4 |
Inkeun Park, Jae Lyun Lee. Systemic treatment for advanced urothelial cancer: an update on recent clinical trials and current treatment options. The Korean Journal of Internal Medicine 2020; 35(4): 834 doi: 10.3904/kjim.2020.204
|
5 |
Nouha Setti Boubaker, Manuela Spagnuolo, Nesrine Trabelsi, Rahma Said, Aymone Gurtner, Giulia Regazzo, Haroun Ayed, Ahlem Blel, Omar Karray, Ahmed Saadi, Soumaya Rammeh, Mohamed Chebil, Maria Giulia Rizzo, Giulia Piaggio, Slah Ouerhani. miR-143 expression profiles in urinary bladder cancer: correlation with clinical and epidemiological parameters. Molecular Biology Reports 2020; 47(2): 1283 doi: 10.1007/s11033-019-05228-1
|